002007.SHE Hualan Biological EngineeringInc
- Market cap
- CNY 21.9B
- P/E
- 37.6x
- P/B
- 2.06x
- ROE
- 5.4%
- Dividend yield
- 6.20%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002007.SHE undervalued?
Graham number002007.SHE trades 85.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hualan Biological EngineeringInc fundamental analysis
No fundamental analysis for Hualan Biological EngineeringInc yet.
Hualan Biological EngineeringInc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various t…
Full company profileHualan Biological EngineeringInc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hualan Biological EngineeringInc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.93B | 2.37B | 3.22B | 3.70B | 5.02B | 4.44B | 4.52B | 5.34B | 4.38B | 4.58B | 3.44B |
| Gross Profit | 1.16B | 1.45B | 2.09B | 2.35B | 3.62B | 2.90B | 2.82B | 3.61B | 2.61B | 2.51B | 1.54B |
| Operating Income | 838M | 916M | 1.39B | 1.62B | 2.15B | 1.70B | 1.42B | 2.10B | 1.38B | 1.13B | 523M |
| EBITDA | 923M | 977M | 1.33B | 1.60B | 2.18B | 1.78B | 1.50B | 2.07B | 1.44B | 1.41B | 694M |
| Net Income | 780M | 821M | 1.14B | 1.28B | 1.61B | 1.30B | 1.08B | 1.48B | 1.09B | 940M | 574M |
| EPS | 0.43 | 0.45 | 0.63 | 0.71 | 0.89 | 0.71 | 0.59 | 0.81 | 0.59 | 0.51 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 4.65B | 5.22B | 6.49B | 7.58B | 10.0B | 11.5B | 14.7B | 16.1B | 16.3B | 15.3B | 14.7B |
| Total Liabilities | 215M | 377M | 720M | 699M | 1.94B | 2.47B | 2.53B | 2.68B | 2.46B | 1.81B | 2.36B |
| Shareholders' Equity | 4.22B | 4.67B | 5.53B | 6.54B | 7.53B | 8.34B | 10.4B | 11.4B | 11.9B | 11.5B | 10.7B |
| Cash & Short-term Investments | 1.79B | 1.49B | 2.46B | 3.37B | 4.02B | 3.35B | 3.47B | 3.11B | 3.25B | 4.30B | 1.08B |
| Total Debt | - | - | - | - | 400M | 991M | 1.11B | 709M | 909M | 547M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 330M | 177M | 1.29B | 1.36B | 1.33B | 1.43B | 957M | 1.35B | 1.06B | 1.14B | - |
| Capital Expenditure | 221M | 109M | 183M | 273M | 621M | 811M | 394M | 753M | 256M | 197M | 177M |
| Free Cash Flow | 109M | 68.9M | 1.11B | 1.09B | 704M | 621M | 563M | 592M | 804M | 945M | 320M |
| Ratios | |||||||||||
| ROE | 18.5% | 17.6% | 20.6% | 19.6% | 21.4% | 15.6% | 10.4% | 13.0% | 9.2% | 8.2% | 5.4% |
| ROA | 16.8% | 15.7% | 17.5% | 16.9% | 16.1% | 11.3% | 7.3% | 9.2% | 6.7% | 6.2% | 3.9% |
| Net Profit Margin | 40.3% | 34.7% | 35.4% | 34.7% | 32.1% | 29.3% | 23.8% | 27.7% | 24.8% | 20.6% | 16.7% |
| Debt to Equity | - | - | - | - | 0.05x | 0.12x | 0.11x | 0.06x | 0.08x | 0.05x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hualan Biological EngineeringInc dividends
- Dividend yield
- 6.20%
- Forward dividend
- 1.00 CNY
- Payout ratio
- 144.8%
- Ex-dividend date
- Jun 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.36B | 0.75 | 144.8% |
| 2024 | CNY 468M | 0.26 | 43.0% |
| 2023 | CNY 564M | 0.31 | 38.0% |
| 2022 | CNY 365M | 0.20 | 33.9% |
| 2021 | CNY 564M | 0.31 | 43.4% |
| 2020 | CNY 561M | 0.31 | 34.8% |
| 2019 | CNY 391M | 0.21 | 30.4% |
| 2018 | CNY 275M | 0.15 | 24.2% |
| 2017 | CNY 397M | 0.22 | 48.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Apr 27, 2020.
Who owns Hualan Biological EngineeringInc
- Insiders 48.69%
- Institutions 5.90%
- Public & others 45.41%
- Shares outstanding 1.83B
- Free float 961M
Hualan Biological EngineeringInc company profile
- Company name
- Hualan Biological EngineeringInc
- Ticker
- 002007.SHE
- ISIN
- CNE000001JN8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 10, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,117
- Fiscal year end
- December
- Address
- No. 1, Hualan Avenue, Xinxiang, China, 453003
- Phone
- 86 37 3505 6905
- Website
- hualanbio.com
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines. In addition, the company develops monoclonal antibody drugs and biosimilars comprising rituximab injection which is in Phase III clinical trials for the treatment of CD20-positive diffuse large B-cell/follicular non-Hodgkin lymphoma and chronic lymphocytic leukemia; adalimumab injection which is in Phase III clinical trials for the treatment of various autoimmune diseases; denosumab injection which is in Phase III clinical trials for the treatment of patients with bone metastases; injectable trastuzumab which is in Phase III clinical trials for the treatment of HER2-positive metastatic/early-stage breast cancer and metastatic gastric cancer; and recombinant Exendin-4-FC fusion protein injection which is in Phase I/II clinical trials for the treatment of type 2 diabetes. Further, it is involved in the research and development of poultry farming; plasma collection; engineering technology research and experimental development; and inspection and testing services. The company was founded in 1992 and is headquartered in Xinxiang, China.
Hualan Biological EngineeringInc management
7- Ms. Bei FanGM & Director · born 1972
- Ms. Ping LinCFO & Accounting Supervisor
- Mr. Bao Xian ZhangDeputy GM & Director · born 1971
- Mr. Yuancheng LouBoard Secretary · born 1984
- Mr. Xiao Wei MaExecutive Deputy General Manager · born 1968
- Ms. Jun LiuDeputy General Manager · born 1976
- Mr. Zhengyue ChenDeputy General Manager · born 1961